Corneal Endothelial Dystrophy Market Expected to rise, 2034 | Trefoil Therapeutics, Aerie Pharmaceuticals, Kowa Research Institute, Inc., Emmecell, Surrozen, expected to drive market

The Corneal Endothelial Dystrophy market growth is driven by factors like increase in the prevalence of Corneal Endothelial Dystrophy, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Corneal Endothelial Dystrophy market report [https://www.delveinsight.com/report-store/corneal-endothelial-dystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Corneal Endothelial Dystrophy market size, share, Corneal Endothelial Dystrophy epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Corneal Endothelial Dystrophy market size growth forward.

Some of the key highlights from the Corneal Endothelial Dystrophy Market Insights Report:

*
Several key pharmaceutical companies, including Trefoil Therapeutics, Aerie Pharmaceuticals, Kowa Research Institute, Inc., Emmecell, Surrozen, and others, are developing novel products to improve the Corneal Endothelial Dystrophy treatment outlook.

*
DelveInsight estimates that in 2023, there were around 18 million prevalent cases of Corneal Endothelial Dystrophy across the 7MM. The United States accounted for approximately 37% of these cases, while the EU4 and the UK countries represented about 46%, with Japan making up nearly 16%. The Corneal Endothelial Dystrophy market is expected to experience steady growth, with an 8% compound annual growth rate (CAGR) projected from 2024 to 2034. This growth is driven by the introduction of new therapies such as Sirolimus and TTHX1114, along with an aging population, increased awareness, better diagnosis, and innovations in pharmaceutical treatments.

*
However, there remains an unmet need for effective, non-invasive, FDA-approved drugs, as current treatments are largely limited to corneal transplants, which involve risks and challenges. This highlights the need for advancements in therapies focused on endothelial regeneration and long-term disease management. A major barrier to treatment is the high cost and limited availability of corneal transplant procedures, compounded by a shortage of donor corneas and specialized surgical expertise, which limits the widespread adoption of advanced therapeutic solutions.

*
As per DelveInsight analysis, the Corneal Endothelial Dystrophy market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Corneal Endothelial Dystrophy Market Landscape [https://www.delveinsight.com/sample-request/corneal-endothelial-dystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Corneal Endothelial Dystrophy Overview

Fuchs' Endothelial Dystrophy (FED), a rare genetic disorder affecting the endothelial layer of the cornea, leads to the accumulation of guttae deposits and subsequent cell death, causing corneal edema and visual disturbances like glare, halos, and reduced acuity. The disease is progressive, bilateral, and more common in females. Advanced stages of FED may involve the development of painful corneal blisters, which can further impair vision and potentially lead to blindness.

Diagnosis is based on a detailed clinical exam, including slit-lamp biomicroscopy to detect guttae, specular or confocal microscopy to assess endothelial cell density, corneal pachymetry to measure edema progression, and optical coherence tomography (OCT) for detailed imaging of the corneal layers. Visual acuity testing and corneal topography are also used to evaluate vision and structural changes.

Management focuses on preserving vision and improving corneal clarity. For early stages, hypertonic saline drops can reduce corneal edema temporarily. In advanced cases, surgical treatments like Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK) or Descemet Membrane Endothelial Keratoplasty (DMEK) can replace damaged endothelial cells. Non-surgical solutions, such as scleral lenses, may also be used to improve visual acuity by minimizing corneal distortion.

Do you know the treatment paradigms for different countries? Download our Corneal Endothelial Dystrophy Market Sample Report [https://www.delveinsight.com/sample-request/corneal-endothelial-dystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Corneal Endothelial Dystrophy Epidemiology Insights

*
According to DelveInsight's epidemiology model, in 2023, the US had approximately 6.6 million prevalent cases of Corneal Endothelial Dystrophy, a number expected to increase during the forecast period (2024-2034) due to factors such as an aging population, genetic predisposition, and advancements in diagnostic techniques.

*
In the EU4 and the UK, Germany reported the highest number of prevalent cases, with around 2.1 million cases in 2023, followed by Italy and France with about 1.6 million cases each.

*
Gender-specific data in the US for 2023 revealed approximately 4.7 million cases in females and 1.9 million cases in males.

*
In Japan, the 50-59 age group had the highest prevalence of Corneal Endothelial Dystrophy in 2023, with around 869 thousand cases. Regarding severity, Japan reported approximately 2.7 million mild cases and about 144 thousand moderate to severe cases.

Corneal Endothelial Dystrophy Epidemiology Segmentation

DelveInsight's Corneal Endothelial Dystrophy market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Corneal Endothelial Dystrophy historical patient pools and forecasted Corneal Endothelial Dystrophy patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Corneal Endothelial Dystrophy Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

*
Corneal Endothelial Dystrophy Prevalence

*
Age-Specific Corneal Endothelial Dystrophy Prevalence

*
Gender-Specific Corneal Endothelial Dystrophy Prevalence

*
Diagnosed and Treatable Cases of Corneal Endothelial Dystrophy

Visit for more @ Corneal Endothelial Dystrophy Epidemiological Insights [https://www.delveinsight.com/report-store/corneal-endothelial-dystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Corneal Endothelial Dystrophy Market Outlook

The treatment approach for Corneal Endothelial Dystrophy primarily focuses on managing symptoms and utilizing surgical interventions, with corneal transplantation being a key option for advanced cases. Current treatments, like topical hypertonic saline drops, offer temporary relief from corneal edema but do not impact the progression of the disease. Surgical advancements, particularly in endothelial keratoplasty techniques such as DSAEK and DMEK, have greatly improved patient outcomes by reducing complications and enabling earlier intervention. New therapies, such as sirolimus eye drops, are being studied for their potential to target the underlying mechanisms of Fuchs Endothelial Corneal Dystrophy by supporting endothelial cell health. Additionally, TTHX1114, an engineered form of FGF1, is being investigated for its ability to promote corneal wound healing and protect endothelial cells. These innovative treatments may enhance the current options available, offering hope for better management and possibly altering the course of the disease.

Corneal Endothelial Dystrophy Emerging Drugs

*
Sirolimus: Santen Pharmaceutical

*
TTHX1114: Trefoil Therapeutics

Corneal Endothelial Dystrophy Key Companies

*
Trefoil Therapeutics, Aerie Pharmaceuticals, Kowa Research Institute, Inc., Emmecell, Surrozen, and others

For more information, visit Corneal Endothelial Dystrophy Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/corneal-endothelial-dystrophy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Corneal Endothelial Dystrophy Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Corneal Endothelial Dystrophy, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Corneal Endothelial Dystrophy epidemiology in the 7MM

*
Corneal Endothelial Dystrophy marketed and emerging therapies

*
Corneal Endothelial Dystrophy companies

*
Corneal Endothelial Dystrophy market drivers and barriers

Table of Contents:

1 Corneal Endothelial Dystrophy Market Key Comprehensive Insights

2 Corneal Endothelial Dystrophy Market Report Introduction

3 Competitive Intelligence Analysis for Corneal Endothelial Dystrophy

4 Corneal Endothelial Dystrophy Market Analysis Overview at a Glance

5 Executive Summary of Corneal Endothelial Dystrophy

6 Corneal Endothelial Dystrophy Epidemiology and Market Methodology

7 Corneal Endothelial Dystrophy Epidemiology and Patient Population

8 Corneal Endothelial Dystrophy Patient Journey

9 Corneal Endothelial Dystrophy Treatment Algorithm, Corneal Endothelial Dystrophy Current Treatment, and Medical Practices

10 Key Endpoints in Corneal Endothelial Dystrophy Clinical Trials

11 Corneal Endothelial Dystrophy Marketed Therapies

12 Corneal Endothelial Dystrophy Emerging Therapies

13 Corneal Endothelial Dystrophy: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Corneal Endothelial Dystrophy

16 Corneal Endothelial Dystrophy Market Key Opinion Leaders Reviews

18 Corneal Endothelial Dystrophy Market Drivers

19 Corneal Endothelial Dystrophy Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Corneal Endothelial Dystrophy Epidemiology 2034

DelveInsight's "Corneal Endothelial Dystrophy - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Corneal Endothelial Dystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Corneal Endothelial Dystrophy Pipeline 2024

"Corneal Endothelial Dystrophy Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Corneal Endothelial Dystrophy market. A detailed picture of the Corneal Endothelial Dystrophy pipeline landscape is provided, which includes the disease overview and Corneal Endothelial Dystrophy treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=corneal-endothelial-dystrophy-market-expected-to-rise-2034-trefoil-therapeutics-aerie-pharmaceuticals-kowa-research-institute-inc-emmecell-surrozen-expected-to-drive-market]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.